PMID- 23957567
OWN - NLM
STAT- MEDLINE
DCOM- 20141121
LR  - 20180816
IS  - 1600-0447 (Electronic)
IS  - 0001-690X (Linking)
VI  - 129
IP  - 5
DP  - 2014 May
TI  - Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar 
      disorder: an open-label trial.
PG  - 393-400
LID - 10.1111/acps.12192 [doi]
AB  - OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is consistently associated 
      with acute mood episodes in bipolar disorder, but there is a lack of longitudinal 
      data to support this hypothesis. In this 16-week open-label clinical trial, we 
      tested the predictive role of BDNF Val66Met polymorphism on serum BDNF levels and 
      the relationship of serum BDNF and clinical response in people with bipolar 
      disorder during an acute illness episode. METHOD: Sixty-four people with bipolar 
      disorder who were medication-free at baseline and in an acute mood episode were 
      recruited. They were matched with 64 healthy controls. Clinical evaluation, serum 
      BDNF, and BDNF Val66Met polymorphism were determined at baseline, and change in 
      serum BDNF was assessed in patients at weeks 2, 4, 8 and 16. RESULTS: There were 
      no differences between patients and controls in serum BDNF or in frequencies of 
      the BDNF Val66Met polymorphism genotype at baseline. The multivariable model 
      showed that Met carriers had a significantly different change in BDNF levels 
      compared with Val homozygotes. Not achieving a complete remission was also 
      associated with lower prospectively assessed BDNF levels. CONCLUSION: This study 
      provides the first longitudinal evidence that both the BDNF Val66Met polymorphism 
      and remission status predict change in circulating BDNF levels.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Grande, I
AU  - Grande I
AD  - Bipolar Disorders Unit, IDIBAPS, CIBERSAM, Clinical Institute of Neurosciences, 
      Hospital Clinic, University of Barcelona, Barcelona, Spain.
FAU - Magalhaes, P V S
AU  - Magalhaes PV
FAU - Chendo, I
AU  - Chendo I
FAU - Stertz, L
AU  - Stertz L
FAU - Fries, G R
AU  - Fries GR
FAU - Cereser, K M
AU  - Cereser KM
FAU - Cunha, A B M
AU  - Cunha AB
FAU - Goi, P
AU  - Goi P
FAU - Kunz, M
AU  - Kunz M
FAU - Udina, M
AU  - Udina M
FAU - Martin-Santos, R
AU  - Martin-Santos R
FAU - Frey, B N
AU  - Frey BN
FAU - Vieta, E
AU  - Vieta E
FAU - Kapczinski, F
AU  - Kapczinski F
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130820
PL  - United States
TA  - Acta Psychiatr Scand
JT  - Acta psychiatrica Scandinavica
JID - 0370364
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Psychotropic Drugs)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - AE28F7PNPL (Methionine)
RN  - HG18B9YRS7 (Valine)
SB  - IM
MH  - Adult
MH  - Affect/physiology
MH  - *Affective Symptoms/blood/diagnosis/genetics
MH  - Amino Acid Substitution/genetics
MH  - Biomarkers/blood
MH  - *Bipolar Disorder/blood/diagnosis/drug therapy/genetics/psychology
MH  - *Brain-Derived Neurotrophic Factor/blood/genetics
MH  - Brazil
MH  - Drug Monitoring/methods
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Methionine/genetics
MH  - Neuronal Plasticity
MH  - Patient Acuity
MH  - Polymorphism, Genetic
MH  - Psychiatric Status Rating Scales
MH  - Psychotropic Drugs/*pharmacology
MH  - Valine/genetics
OTO - NOTNLM
OT  - biomarkers
OT  - bipolar disorder
OT  - brain-derived neurotrophic factor
OT  - quetiapine
OT  - treatment response
EDAT- 2013/08/21 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/08/21 06:00
PHST- 2013/07/11 00:00 [accepted]
PHST- 2013/08/21 06:00 [entrez]
PHST- 2013/08/21 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/acps.12192 [doi]
PST - ppublish
SO  - Acta Psychiatr Scand. 2014 May;129(5):393-400. doi: 10.1111/acps.12192. Epub 2013 
      Aug 20.